Figure 4. The oral administration of LG2055 has a potentiating effect that enables it to induce the antiviral genes in the lung tissues.

(a, b) LG2055 (1.0 × 10⁹ cfu/mouse; open bars), or 25% trehalose solution (closed bars) was orally administered to C57BL/6N mice for 7 days. After the LG2055 pre-treatment, the gene expression of Mx1, Oas1a, IFN-β, and Stat2 in lung tissue (n = 9/group) (a) and alveolar macrophage (n = 9/group) (b) was assessed by real-time PCR. (c, d) RAW264.7 cells were stimulated with 100 μg/ml of LG2055 (closed bars) or PBS (open bars). At the each time point after stimulation, the cells were harvested, and the total RNAs isolated from the cells were subjected to the real-time PCR analysis using specific primer sets for IFN-β (c) and Mx1 (d) (n = 3/each time point). (e) RAW264.7 cells were infected with PR8 virus (MOI = 1), and then the cells were harvested at some time points of post-infection indicated in the figure. Total RNAs isolated from the cells were then analyzed by real-time RT-PCR using specific primer sets for PR8-NP. (f) RAW264.7 cells were stimulated with LG2055 (100 μg/ml) for 24 hrs, and then the PR8 virus was infected to the cells (MOI = 1). After the incubation, the virus titers in the cultured medium were measured by plaque assay. Data are presented as means ± SEM. *: p < 0.05. ***: p < 0.001.